BNTC stock forecast, quote, news & analysis
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on advancing novel genetic medicines... Show more
Why Benitec Biopharma (BNTC) Stock Is Down -20% in the Last 30 Days
Key Takeaways
- Benitec Biopharma (BNTC) shares have fallen roughly 20% over the trailing 30 days, retreating from about $10.88 to near $8.70.
- The decline extends a broader pullback that has left the stock down roughly 27% over the past quarter.
- Benitec is a pre-revenue, clinical-stage gene therapy company whose valuation is tied almost entirely to its lead program, BB-301 for oculopharyngeal muscular dystrophy (OPMD).
- A Type C meeting with the U.S. FDA kept the BB-301 pivotal study on track for a mid-2027 start but confirmed the agency requested additional data, a near-term overhang on sentiment.
- The company filed a $200 million mixed securities shelf, which can raise dilution concerns for a cash-burning biotech.
- Sell-side analysts remain constructive, with a consensus Strong Buy rating and an average price target well above current levels.
Benitec Biopharma (BNTC) Company Overview and Market Position
Benitec Biopharma Inc. is a clinical-stage biotechnology company headquartered in Hayward, California, focused on developing novel genetic medicines built on its proprietary "Silence and Replace" DNA-directed RNA interference (ddRNAi) platform. The technology combines sustained silencing of a disease-causing gene with delivery of a functional replacement gene following a single administration of the therapeutic construct.
Its lead candidate, BB-301, is an AAV-based gene therapy being evaluated in a Phase 1b/2a study for oculopharyngeal muscular dystrophy (OPMD) related dysphagia. BB-301 is the only clinical-stage therapeutic agent in development for the condition, which positions Benitec in a largely uncontested niche. As a pre-revenue company with no approved products, the stock is driven primarily by clinical data readouts, regulatory milestones, and balance-sheet runway rather than conventional earnings metrics.
Benitec Biopharma (BNTC) Stock Price Performance: Last 30 Days vs. Quarter
Over the trailing 30 days, BNTC has declined roughly 20%, moving from a level near $10.88 to about $8.70. The move reflects a steady slide through late September and October punctuated by occasional short-lived bounces, and it has left the shares trading near the lower end of their 52-week range of $8.00 to $16.76.
The recent weakness is consistent with a longer deterioration. Over the past quarter, the stock has fallen roughly 27%, from about $11.89 to near $8.70. Within that three-month window, shares rallied to an intraday high near $13.95 in mid-August before reversing lower, illustrating how quickly sentiment can shift in a single-asset, clinical-stage biotech story.
What Drove BNTC Stock Price in the Last 30 Days
Several verified developments shaped the recent decline. In early October, Benitec announced the outcome of a Type C meeting with the FDA regarding the BB-301 pivotal study. While the company reiterated that the pivotal trial remains on track to begin in mid-2027, it also disclosed that the FDA requested additional available data as discussions around an open-label, single-arm design continue. For investors, the request for more information added a degree of near-term uncertainty around the regulatory path.
The company also released full-year fiscal 2026 results and an operational update in mid-September, reporting that all six Cohort 1 (low-dose) patients completed the 12-month post-treatment follow-up period and that Cohort 2 (high-dose) is fully enrolled with all three patients safely treated. Separately, Benitec filed a $200 million mixed securities shelf, which can weigh on sentiment by raising the prospect of future dilution for a company that is not yet generating product revenue.
On the analyst front, views remained broadly constructive even as the shares fell. Wedbush raised its price target to $17 from $16 while maintaining an Outperform rating, and other firms have reiterated above-market targets. The slide therefore appears tied more to regulatory uncertainty, dilution concerns, and broader risk-off pressure across the biotechnology sector than to a deterioration in the underlying clinical story.
What Drove BNTC Stock Performance Over the Last Quarter
The quarterly decline followed a strong run for the shares earlier in the year. Positive BB-301 data flow, including an oral presentation of interim Phase 1b/2a results at the 2026 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting and a late-breaking abstract at the Muscular Dystrophy Association conference, helped push the stock toward its summer highs near $13.95 in mid-August.
From that peak, momentum faded. The FDA's request for additional data ahead of the pivotal trial, the shelf registration, and a broader pullback in small- and mid-cap biotechnology names contributed to a multi-month decline. Because Benitec's valuation is concentrated in a single clinical asset, the stock has been especially sensitive to shifts in regulatory expectations and risk appetite, amplifying the downside move through September and October.
Trending AI Robots
For traders seeking a data-driven approach to navigating fast-moving stocks, Tickeron's Trending AI Robots page offers a curated view of its AI-powered trading tools. Tickeron hosts hundreds of AI trading bots that monitor thousands of tickers, but only the top-performing and most relevant robots are surfaced in this section, helping users cut through the noise. These bots vary widely in strategy, timeframe, and performance metrics, giving traders the flexibility to find approaches aligned with their own objectives and risk tolerance. Exploring the page can provide a useful starting point for those looking to complement their research with automated, quantitative signals.
BNTC Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, the primary catalyst for BNTC remains the BB-301 program. Investors will be watching for updated interim clinical results from the Phase 1b/2a study, which the company has indicated it expects to report in the second half of 2026, as well as further clarity from the FDA on the pivotal study design and the targeted mid-2027 start.
Other factors to monitor include the company's next quarterly earnings release and cash position, given that Benitec reported cash of approximately $184.8 million as of March 31, 2026, and must fund the program through the completion of the pivotal study. Dilution risk tied to the registered shelf, evolving analyst price targets, and the broader climate for clinical-stage biotechnology valuations will also influence the shares. As always, these are informational considerations rather than investment recommendations.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
BNTC's RSI Indicator climbs out of oversold territory
The RSI Oscillator for BNTC moved out of oversold territory on October 19, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 22 similar instances when the indicator left oversold territory. In 19 of the 22 cases the stock moved higher. This puts the odds of a move higher at 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on BNTC as a result. In 87 of 102 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.
The Moving Average Convergence Divergence (MACD) for BNTC just turned positive on October 20, 2026. Looking at past instances where BNTC's MACD turned positive, the stock continued to rise in 38 of 47 cases over the following month. The odds of a continued upward trend are 81%.
Following a +14.24% 3-day Advance, the price is estimated to grow further. Considering data from situations where BNTC advanced for three days, in 226 of 271 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
The 50-day moving average for BNTC moved below the 200-day moving average on October 06, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BNTC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
BNTC broke above its upper Bollinger Band on November 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for BNTC entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 21 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating steady price growth. BNTC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 84 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.880) is normal, around the industry mean (3.498). P/E Ratio (-9.735) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. BNTC's P/S Ratio (2500.000) is slightly higher than the industry average of (440.869).
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BNTC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a biotechnology, research and development company
Industry Biotechnology